185. Deputy Holly Cairns asked the Minister for Health the status of public funding application for a medication (details supplied) when prescribed in the treatment of the chronic inflammatory condition eosinophilic esophagitis (EoE); and if she will make a statement on the matter. [45990/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
188. Deputy Louis O'Hara asked the Minister for Health whether the reimbursement of the drug skyclarys was included in the agenda for the June meeting of the HSE's Drugs Groups; if not, the rationale for its exclusion; to provide an update on the process of adjudicating whether the cost of skyclarys will be reimbursed; and if she will make a statement on the matter. [46002/26]
211. Deputy Pádraig Rice asked the Minister for Health if the consideration of skyclarys for the treatment of Friedreich's ataxia will be prioritised; the date on which the drug will be on the agenda for a meeting of the HSE Drugs Group; and if she will make a statement on the matter. [46123/26]
212. Deputy Peter 'Chap' Cleere asked the Minister for Health further to Parliamentary Question No. 859 of 6 May 2026, if the HSE will issue a response to this Deputy as soon as possible. [46142/26]
821. Deputy Conor Sheehan asked the Minister for Health the reason Skyclarys is not included on the agenda for the upcoming HSE drugs group meeting; if this drug will be put on the agenda for this meeting; and if she will make a statement on the matter. [44885/26]
823. Deputy Paul Nicholas Gogarty asked the Minister for Health the actions she is taking in liaison with the HSE to ensure a timely pricing and reimbursement scheme for givinostat (duvyzat), given that it is a year since conditional marketing authorisation was granted and it is a year since she met with families of children with DM and MDI and six months since she spoke at a national conference (details supplied); a…
824. Deputy Paul Nicholas Gogarty asked the Minister for Health the reasons provided by the HSE regarding the delay in processing the pricing and reimbursement application for givinostat, especially since 15 January 2026 when a full HTA dossier was submitted by a company (details supplied) to the NCPE; and if she will make a statement on the matter. [44892/26]
825. Deputy Paul Nicholas Gogarty asked the Minister for Health if she has been briefed by the HSE Drugs Group which was due to meet on 10 June 2026 to consider givinostat for reimbursement; if clear timelines for rollout have now been provided; if there will be proactive engagement with the HSE and clinical teams to ensure planning begins urgently, in order that implementation does not become a further barrier to ac…
826. Deputy Paul Nicholas Gogarty asked the Minister for Health the steps she has taken to ensure that eligibility criteria for givinostat are aligned with the NICE approach, ensuring access for boys who can walk or who can stand with or without support, in order that boys here are not disadvantaged compared to those in the Northern Ireland and receive equitable access to treatment; and if she will make a statement o…
830. Deputy Eoghan Kenny asked the Minister for Health if her Department has further considered the inclusion of Skyclarys (omaveloxolone) as of June 2026, which is a treatment for Friedreich's ataxia in a reimbursement scheme given the cost of the drug and the fact that other European countries provide this scheme to patients; and if she will make a statement on the matter. [44904/26]
832. Deputy Claire Kerrane asked the Minister for Health to provide an update on access to givinostat; and if she will make a statement on the matter. [44908/26]
833. Deputy Claire Kerrane asked the Minister for Health if she will consider including mounjaro on the medical card scheme for medical card holders aged over 70; and if she will make a statement on the matter. [44909/26]
836. Deputy Michael Fitzmaurice asked the Minister for Health the status of gaining access to givinostat for boys living with Duchenne muscular dystrophy; and if she will make a statement on the matter. [44919/26]
838. Deputy Claire Kerrane asked the Minister for Health the steps she will take to ensure that the HSE recognises and responds to the time-critical nature of Friedreich's ataxia during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [44928/26]
839. Deputy Shónagh Ní Raghallaigh asked the Minister for Health if she will ensure free access to givinostat for boys living with Duchenne muscular dystrophy; and if she will make a statement on the matter. [44935/26]
842. Deputy Michael Cahill asked the Minister for Health to ensure that all children within the State receive urgent access to givinostat (duvyzat) for Duchenne muscular dystrophy (details supplied); and if she will make a statement on the matter. [44945/26]
852. Deputy William Aird asked the Minister for Health the current status of the reimbursement application for givinostat for the treatment of boys living with Duchenne muscular dystrophy; the timeline for a decision following consideration by the HSE Drugs Group; the steps being taken to ensure that there are no further delays in access should reimbursement be approved; whether eligibility criteria will be aligned w…
853. Deputy Willie O'Dea asked the Minister for Health if she will expedite the approval and funding of the new drug givinostat to treat boys currently living with Duchenne muscular dystrophy (DMD) in Ireland; and if she will make a statement on the matter. [44978/26]
857. Deputy James Geoghegan asked the Minister for Health to review correspondence (details supplied) [45010/26]
864. Deputy Roderic O'Gorman asked the Minister for Health to provide an update on consideration of the HSE corporate pharmaceutical unit of reimbursement of givinostat for Duchenne muscular dystrophy; and if she will make a statement on the matter. [45076/26]
868. Deputy Roderic O'Gorman asked the Minister for Health the reason consideration of reimbursement for skyclarys was not included in the agenda for the 10 June 2026 meeting of the HSE's corporate pharmaceutical unit; and if she will make a statement on the matter. [45086/26]
877. Deputy Michael Cahill asked the Minister for Health if she will ensure Skyclarys is covered by the HSE as it is the only drug approved to treat Friedreich's ataxia; and if she will make a statement on the matter. [45121/26]
884. Deputy Mark Ward asked the Minister for Health if givinostat will be made available for children with Duchenne muscular dystrophy; to provide an update on steps taken by the HSE since a commercial proposal was received from a company (details supplied); when this therapy will be made available to the public; and if she will make a statement on the matter. [45156/26]
898. Deputy Duncan Smith asked the Minister for Health when givinostat will be made available for boys with Duchenne muscular dystrophy; and if she will make a statement on the matter. [45208/26]
929. Deputy Marie Sherlock asked the Minister for Health for an update on the reimbursement process for Skyclarys for persons living with Friedreich’s ataxia; and if she will make a statement on the matter. [45289/26]